Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
16 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
EPM Pharma Invest from Sint-Martens-Latem, company number BE0538590817, closed financial year 2025 with a result of € -33,175 after tax. For that financial year EPM Pharma Invest recorded a gross margin of € -66 and equity of € 109,705. Compared with financial year 2024, the result moved from € 1,290 to € -33,175. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 109,705
▼ 23% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -33,175
▼ still € 1,290 profit in 2024
Profit after tax over the fiscal year.
€ 3,607
▼ 8% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -845,948.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 510
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -57 | € -1,706 | € -64 | € -66 | ▼ € 2 |
| Profit after taxes | € -30,856 | € -8,919 | € 1,290 | € -33,175 | ▼ € 34,465 |
| Equity | € 150,510 | € 141,591 | € 142,881 | € 109,705 | ▼ 23% |
| Total debts | € 110 | € 1,956 | € 387 | € 510 | ▲ 32% |
| Cash | € 22,151 | € 21,282 | € 3,938 | € 3,607 | ▼ 8% |
| Retained profit | € -805,144 | € -814,063 | € -812,773 | € -845,948 | ▼ € 33,175 |
| Balance sheet total | € 150,620 | € 143,547 | € 143,268 | € 110,215 | ▼ 23% |
Key figures of EPM Pharma Invest, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EPM Pharma Invest?
What happened at EPM Pharma Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 33,175 (▼ € 34,465 vs 2024). Source: NBB ↗
- New establishment in Sint-Martens-Latem. KBO
- NESCH INVEST BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 30,856 loss in 2022 to € 33,175 loss in 2025.
Best year ever: 2024, with € 1,290 profit.
A new publication or filing at EPM Pharma Invest? We notify you, reason included.
Follow EPM Pharma InvestDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PhiDeX Inc. comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EPM Pharma InvestBehind EPM Pharma Invest is NESCH INVEST BV. The shares are held by PhiDeX Inc. (68.6%).
Directors
According to the 2025 annual accounts
Director · represented by Geert Van Gijseghem
Also active at: MAB Consult Europe, RXW Group, PhiDeX Inc., PHIDEX CALN, Advantage Real Estate, CFG Pharma, B+INVEST, B+invest2 +1 more
since 2013
Shareholders
68.6%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 180 box 4 C
9830 Sint-Martens-Latem
Kortrijksesteenweg 180 box 4c
9830 Sint-Martens-Latem
Active since 13 September 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.
All companies at this address →ADMISOL
€ 1.6 million gross margin · 2025
MAB Consult Europe same network
€ -849 gross margin · 2025
CASA GRANDE
€ 373,195 gross margin · 2025
RXW Group same network
€ -140,092 gross margin · 2025
LES AMIS DE NORBERT
€ -9,140 gross margin · 2025
+11 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0538.590.817
- VAT number
- BE 0538.590.817
- Registered office
- Kortrijksesteenweg 180 bus 4 C, 9830 Sint-Martens-Latem
- Names & denominations
- EPM Pharma Invest
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 September 2013
- Peppol
- Not registered